Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Passes Below Fifty Day Moving Average - What's Next?

Adaptimmune Therapeutics PLC (NASDAQ:ADAP - Get Free Report)'s stock price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.27 and traded as low as $0.25. Adaptimmune Therapeutics shares last traded at $0.26, with a volume of 465,729 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ADAP shares. Scotiabank cut their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. Barclays lowered their price target on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating on the stock in a report on Wednesday, May 14th. HC Wainwright dropped their price objective on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Guggenheim decreased their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. Finally, Wells Fargo & Company lowered their target price on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1.52.

Adaptimmune Therapeutics Stock Down 0.1%

The firm has a market cap of $67.85 million, a price-to-earnings ratio of -0.95 and a beta of 2.24. The business's 50-day moving average is $0.27 and its 200-day moving average is $0.43. The company has a debt-to-equity ratio of 4.24, a quick ratio of 1.79 and a current ratio of 2.02.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18). Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative return on equity of 163.73%. The company had revenue of $7.29 million during the quarter, compared to analyst estimates of $6.55 million. On average, equities analysts predict that Adaptimmune Therapeutics PLC will post -0.14 EPS for the current year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ADAP. Renaissance Technologies LLC raised its stake in shares of Adaptimmune Therapeutics by 52.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock worth $1,361,000 after acquiring an additional 869,949 shares during the last quarter. Two Sigma Advisers LP increased its holdings in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 58,787 shares in the last quarter. Two Seas Capital LP acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $7,992,000. Jane Street Group LLC raised its position in Adaptimmune Therapeutics by 87.7% in the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company's stock worth $176,000 after purchasing an additional 152,780 shares during the last quarter. Finally, Long Focus Capital Management LLC lifted its holdings in Adaptimmune Therapeutics by 54.1% during the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock worth $11,040,000 after buying an additional 7,194,503 shares in the last quarter. 31.37% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.